BioVie Inc. (NASDAQ:BIVI – Get Free Report) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 2,090,000 shares, an increase of 13.6% from the November 30th total of 1,840,000 shares. Based on an average daily volume of 5,990,000 shares, the short-interest ratio is currently 0.3 days.
BioVie Stock Down 4.3 %
BioVie stock traded down $0.09 during midday trading on Tuesday, hitting $2.00. 1,194,668 shares of the stock were exchanged, compared to its average volume of 1,662,104. The stock has a market capitalization of $35.54 million, a price-to-earnings ratio of -0.17 and a beta of 0.40. BioVie has a 52-week low of $1.04 and a 52-week high of $33.10. The business’s 50-day moving average price is $2.75 and its 200-day moving average price is $1.94.
BioVie (NASDAQ:BIVI – Get Free Report) last released its earnings results on Monday, September 30th. The company reported ($6.60) earnings per share (EPS) for the quarter.
BioVie Company Profile
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
Further Reading
- Five stocks we like better than BioVie
- Stock Dividend Cuts Happen Are You Ready?
- 3 Stocks Helping to Bring AI to Healthcare
- Financial Services Stocks Investing
- 3 Stocks Ringing in The New Year With Large Buyback Announcements
- What is a Stock Market Index and How Do You Use Them?
- Why 2024 Was Great for Stocks—and Why 2025 Could Be Even Better
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.